Seres Therapeutics (MCRB) Analyst & Key Data

Analyst Consensus

Buy1 analysts

Buy

Updated Sep 12, 2026

Total Analysts1

Buy

11

Hold

3

Sell

4

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.01

Median Target+139.52%

$12.00

Potential upside vs current price

DCF Value-163.41%

-$3.18

Potential downside vs current price

Current Stock Price

$5.01

Median Target+139.52%

$12.00

Potential upside vs current price

DCF Value-163.41%

-$3.18

Potential downside vs current price

Analyst Consensus

Buy1 analysts

Buy

Updated Sep 12, 2026

Total Analysts1

Buy

11

Hold

3

Sell

4

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.01

Median Target+139.52%

$12.00

Potential upside vs current price

DCF Value-163.41%

-$3.18

Potential downside vs current price

Current Stock Price

$5.01

Median Target+139.52%

$12.00

Potential upside vs current price

DCF Value-163.41%

-$3.18

Potential downside vs current price

Seres Therapeutics, Inc.